Next generation immune cell engagers for cancer
Cytospire Therapeutics is a UK-based clinical-stage biotechnology company developing next-generation multispecific immune cell engagers for cancer treatment. Its lead programs are pan-gamma delta (γδ) T cell engagers designed to direct the innate and adaptive immune system against tumors, offering a safer and more tailored alternative to CD3-based engagers. The company was founded by leadership previously at Adaptate Biotherapeutics and GammaDelta Therapeutics, both acquired by Takeda Pharmaceuticals, and raised an oversubscribed £61 million ($83M) Series A in May 2026 led by 4BIO Capital.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2026
May 2026
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
